drugset / Trial / NCT02170675
Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To investigate whether and to what extent the P-glycoprotein (P-gp) inhibitor ketoconazole affects plasma exposure of dabigatran.
Timeline
- Start
- 2009-06
- Primary completion
- 2009-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 150 mg | — |
| Subject | Ketoconazole | Small molecule | 400 mg | — |
Indications
No indication recorded.